American Society of Hematology

ASH, the world's largest professional society concerned with the causes and treatments of blood disorders, regularly issues press releases highlighting clinical and research advances announced at the ASH annual meeting and published in Blood, as well as releases and statements on breaking policy news affecting the field of hematology.

Need to speak with an expert? Complete our Request An Expert form.

To be added to ASH's press release distribution list, contact Amanda Szabo at aszabo@hematology.org.

Latest Press Releases

  • Patients with Adverse Heparin Reaction May Be Ready for Urgent Heart Surgery Sooner with Combination of Blood Screenings, Plasma Exchange Nov 18, 2014

    New evidence suggests that therapeutic plasma exchange and appropriate blood testing could help patients who are in urgent need of heart surgery, but have a history of an adverse reaction to the blood thinner heparin, according to a study published online today in Blood, the Journal of the American Society of Hematology.

  • American Society of Hematology Awards New Bridge Grants to Help Alleviate Pain of Federal Funding Cuts Nov 17, 2014

    The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the names of seven recipients of its Bridge Grant awards. These one-year, $150,000 awards provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the National Institutes of Health (NIH) amid severe funding reductions. The ASH Bridge Grant award recipients announced today join 44 hematologists that have received funding since ASH committed $9 million in Society funds to create the program in July 2012.

  • ASCP and ASH Partner on Grant to Enhance and Expand MDS Curriculum Oct 30, 2014

    The American Society for Clinical Pathology (ASCP) and the American Society of Hematology (ASH) announced today that the two organizations are partnering on an independent educational grant from Summit, N.J.-based Celgene Corporation to update, enhance and expand ASCP’s existing Myelodysplastic Syndromes (MDS) curriculum. This represents the second independent educational grant award by Celgene to ASCP for this program. The curriculum titled, “The Diagnosis, Classification, and Clinical Care of MDS (DC3-MDS),” was developed in 2012 from the first educational grant by Celgene.

View all